echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The test failed!

    The test failed!

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompileKe Ke

    A few days ago, Novartis quietly revealed in its first quarter 2021 financial report that the Phase 3 clinical trial Paradise-MI showed that Entresto missed the primary endpoint of reducing the risk of cardiovascular death and heart failure after acute myocardial infarction.


    In this study, the data of the trial results consistently support that Entresto has a better trend than the standard treatment ramipril, and Entresto has not reached its goal.


    Novartis initiated the Paradise-MI clinical study in 2016 to see if Entresto can surpass the widely used ACE inhibitor ramipril in reducing cardiovascular death and heart failure in patients with heart attacks.


    Although the results of the study are not satisfactory, in terms of sales, Entresto's sales in the first quarter increased by 39% to $789 million, helping Novartis to offset the problem of sales decline caused by competition in the generic drug business.


    Entresto's trial failure occurred shortly after a major victory for the drug's heart failure indication.


    In addition to Entresto's existing studies on patients with chronic heart failure and reduced ejection fraction, the approval also positions the drug as the first and only drug approved in both cases.


    Peter Welford, an analyst at Jefferies, a well-known Wall Street investment bank, wrote in 2020 when an independent team of the US FDA supported the use of the drug in patients with HFpEF, that Entresto's maximum sales are expected to increase by another $1 billion.


    In addition, Novartis’s first quarter 2021 financial report showed that net sales fell by 2% to 12.


    Reference source:

    1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.